Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 3
2004 2
2005 1
2006 1
2007 3
2008 4
2009 4
2010 7
2011 10
2012 8
2013 7
2014 6
2015 11
2016 8
2017 9
2018 6
2019 6
2020 3
2021 6
2022 7
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 29098033

101 results

Results by year

Filters applied: . Clear all
Page 1
High stromal carbonic anhydrase IX expression is associated with nodal metastasis and decreased survival in patients with surgically-treated oral cavity squamous cell carcinoma.
Brockton NT, Klimowicz AC, Bose P, Petrillo SK, Konno M, Rudmik L, Dean M, Nakoneshny SC, Matthews TW, Chandarana S, Lau HY, Magliocco AM, Dort JC. Brockton NT, et al. Oral Oncol. 2012 Jul;48(7):615-22. doi: 10.1016/j.oraloncology.2012.01.018. Epub 2012 Feb 25. Oral Oncol. 2012. PMID: 22366443
Investigation of the Prognostic Role of Carbonic Anhydrase 9 (CAIX) of the Cellular mRNA/Protein Level or Soluble CAIX Protein in Patients with Oral Squamous Cell Carcinoma.
Eckert AW, Horter S, Bethmann D, Kotrba J, Kaune T, Rot S, Bache M, Bilkenroth U, Reich W, Greither T, Wickenhauser C, Vordermark D, Taubert H, Kappler M. Eckert AW, et al. Int J Mol Sci. 2019 Jan 16;20(2):375. doi: 10.3390/ijms20020375. Int J Mol Sci. 2019. PMID: 30654595 Free PMC article.
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial.
Janning M, Müller V, Vettorazzi E, Cubas-Cordova M, Gensch V, Ben-Batalla I, Zu Eulenburg C, Schem C, Fasching PA, Schnappauf B, Karn T, Fehm T, Just M, Kühn T, Holms F, Overkamp F, Krabisch P, Rack B, Denkert C, Untch M, Tesch H, Rezai M, Kittel K, Pantel K, Bokemeyer C, Loibl S, von Minckwitz G, Loges S. Janning M, et al. Int J Cancer. 2019 Aug 1;145(3):857-868. doi: 10.1002/ijc.32163. Epub 2019 Mar 4. Int J Cancer. 2019. PMID: 30694523 Free article. Clinical Trial.
PAI-1, CAIX, and VEGFA expressions as prognosis markers in oral squamous cell carcinoma.
Peterle GT, Maia LL, Trivilin LO, de Oliveira MM, Dos Santos JG, Mendes SO, Stur E, Agostini LP, Rocha LA, Moysés RA, Cury PM, Nunes FD, Louro ID, Dos Santos M, da Silva AMÁ. Peterle GT, et al. J Oral Pathol Med. 2018 Jul;47(6):566-574. doi: 10.1111/jop.12721. Epub 2018 May 15. J Oral Pathol Med. 2018. PMID: 29693741
101 results